What is Leerink Partnrs’ Estimate for Climb Bio Q2 Earnings?

Climb Bio, Inc. (NASDAQ:CLYM) – Research analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Climb Bio in a report released on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.18) for the quarter, down from their prior forecast of ($0.15). The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio’s Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($1.84) EPS and FY2029 earnings at ($2.85) EPS.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.16).

Climb Bio Price Performance

NASDAQ CLYM opened at $1.29 on Monday. The firm has a fifty day moving average of $1.26. The stock has a market cap of $87.17 million, a P/E ratio of -0.61 and a beta of -0.12. Climb Bio has a 12 month low of $1.05 and a 12 month high of $9.58.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new position in shares of Climb Bio in the 1st quarter valued at $27,000. XTX Topco Ltd acquired a new stake in Climb Bio during the 1st quarter worth $34,000. Nuveen LLC acquired a new stake in Climb Bio during the 1st quarter worth $48,000. Bank of New York Mellon Corp acquired a new stake in Climb Bio during the 1st quarter worth $79,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Climb Bio during the 1st quarter worth $86,000. 69.76% of the stock is owned by hedge funds and other institutional investors.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.